Index. Note: Page numbers of article titles are in boldface type.

Transcription

1 Index Note: Page numbers of article titles are in boldface type. A Adaptive therapy, for locally advanced gastroesophageal cancers, 447 Adenocarcinoma, emerging novel therapeutic agents for gastroesophageal and gastric, cancer stem cells, signal transducers and activators of transcription 3 (STAT3) inhibitors, CLDN18.2 inhibitors, fibroblast growth factor receptor 2 (FGFR2) inhibitors, AZD4547, resistance to, 533 role in trastuzumab resistance, 533 matrix metalloproteinase (MMP) inhibitors, marimastat, 541 specific MMP 9 inhibitors, gastroesophageal, targeted therapies for, epidermal growth factor receptor, ERBB2 (HER2), MET, intramucosal esophageal, and Barrett s esophagus, chemoprevention in, NSAIDs, 416 proton pump inhibitors, endoscopic surveillance of, 414 epidemiology, genetics, and natural history of, eradication of dysplasia and reduction of progression, 416 evaluation of, high-grade dysplasia and intramucosal adenocarcinoma, low-grade dysplasia, management objectives in, management of underlying GERD, 415 nondysplastic, predictors of progression, screening for, 414 Adjuvant therapy, chemoradiation for localized gastric cancer, for locally advanced gastroesophageal cancers, chemoradiation, chemotherapy, Anatomic location, of gastroesophageal cancers, impact on management, Antiangiogenic therapy, in gastroesophageal cancer, angiogenesis pathway, 500 inhibitors of VEGF axis via monoclonal antibodies, anti-vegf monoclonal antibody, Hematol Oncol Clin N Am 31 (2017) /17 hemonc.theclinics.com

2 554 Index Antiangiogenic (continued) anti-vegfr2 monoclonal antibody, locally advanced disease, 505 ongoing areas of research, combination with anti-her2 therapy, 506 combination with immune checkpoint therapy, predictive biomarkers, tyrosine kinase inhibition of VEGF axis, 504 apatinib in third-line therapy, 504 regorafenib in second/third-line therapy, 504 Apatinib, for gastroesophageal cancer therapy, 504 Archaea, in gastric microbiome, 394 Avelumab, efficacy in gastroesophageal cancer management, AZD4547, novel therapy for gastroesophageal and gastric adenocarcinomas, B Bacteria. See also Microbiome. esophageal, gastric, Barrett esophagus, and intramucosal esophageal adenocarcinoma, chemoprevention in, NSAIDs, 416 proton pump inhibitors, endoscopic surveillance of, 414 epidemiology, genetics, and natural history of, eradication of dysplasia and reduction of progression, 416 evaluation of, high-grade dysplasia and intramucosal adenocarcinoma, low-grade dysplasia, management objectives in, management of underlying GERD, 415 nondysplastic, predictors of progression, screening for, 414 Biomarkers, predictive, for gastroesophageal cancers, C Cancer stem cells, in novel therapies for gastroesophageal and gastric adenocarcinomas, Carcinogenesis, gastric, influence of gastric microbiome on, community dynamics and pathobionts, diversity of along the GI tract, archaea, 393 esophageal bacteria, fungi, gastric bacteria, viruses, epidemiologic associations with diseases, Epstein-Barr virus, 396

3 Helicobacter pylori, other, 396 evidence for microbiome shifts with prior Helicobacter pylori infection, Epstein-Barr virus, 398 Fusobacterium sp, 399 other species, 399 identification methodologies from clinical samples, computational identification, experimental approaches, 394 molecular associations and mechanisms of carcinogenesis, Helicobacter pylori tumorigenicity, Checkpoint inhibitors, evolving role in esophageal cancer management, adjuvant studies, in combination with antiangiogenic therapy, efficacy of CTLA-4 inhibitors, 491 ipilumumab or tremelimumab, 491 efficacy of PD-1/PD-L1 inhibitors, avelumab, durvalumab, 491 nivolumab, 490 pembrolizumab, localized, role of radiotherapy in, in esophageal cancer, in gastric cancer, locally advanced, management of, differences in anatomic location and histology, multimodal treatment options, options to improve current approaches, overview, 442 PD-L1 expression in, 488 predictive biomarkers to guide use of, gene signatures, 489 mononuclear inflammatory score, PD-L1/PD-L2 status, 488 rationale for investigating, chronic inflammation, 487 genomic instability, 487 high somatic burden, 487 infection, Chemoradiation, for localized esophageal cancer, definitive, neoadjuvant, for localized gastric cancer, adjuvant, neoadjuvant, for locally advanced gastroesophageal cancers, adjuvant, preoperative, Chemotherapy, for locally advanced gastroesophageal cancers, adjuvant, 445 perioperative, for metastatic gastric cancer, Index 555

4 556 Index Chemotherapy (continued) first-line chemotherapy, fluoropyrimidines, for HER2-positive disease, platinum compounds, 472 standard regimens, 475 triplet combinations with epirubicin or docetaxel, second-line chemotherapy, Claudin inhibitors, novel therapy for gastroesophageal and gastric adenocarcinomas, CLDN182 inhibitors, novel therapy for gastroesophageal and gastric adenocarcinomas, Computerized tomography (CT), for staging esophageal and gastric cancers, with positron emission tomography (PET), Cytotoxic T-lymphocyte associated-4 inhibitors, efficacy in gastroesophageal cancer management, 491 ipilumumab, 491 tremelimumab, 491 D Doxorubicin, with triplet combinations in first-line chemotherapy for metastatic gastric cancer, Durvalumab, efficacy in gastroesophageal cancer management, 491 Dysplasia, eradication of, in Barrett s esophagus, 416 high-grade, in Barrett s esophagus, low-grade, in Barrett s esophagus, E Endoscopic resection, for staging esophageal and gastric cancers, Endoscopic surveillance, of Barrett s esophagus, 414 Endoscopic ultrasound, for staging esophageal and gastric cancers, Epidermal growth factor receptor, targeted therapy for gastroesophageal adenocarcinoma, Epirubicin, with triplet combinations in first-line chemotherapy for metastatic gastric cancer, Epstein-Barr virus, epidemiologic association with gastric diseases, 396, 398 epigenetic alterations, 398 latent infection in gastric epithelial cells, 398 viral micrornas, 398 Esophageal cancers. See also Gastroesophageal cancers. intramucosal adenocarcinoma, Barrett esophagus and, chemoprevention in, NSAIDs, 416 proton pump inhibitors, endoscopic surveillance of, 414 epidemiology, genetics, and natural history of, eradication of dysplasia and reduction of progression, 416 evaluation of, high-grade dysplasia and intramucosal adenocarcinoma,

5 Index 557 low-grade dysplasia, management objectives in, management of underlying GERD, 415 nondysplastic, predictors of progression, screening for, 414 staging in, cancer of the gastroesophageal junction, CT, endoscopic ultrasound and endoscopic resection, MRI, 435 PET-CT, staging laparoscopy, 436 F Fibroblast growth factor receptor 2 (FGFR2) inhibitors, for gastroesophageal and gastric adenocarcinomas, AZD4547, resistance to, 533 role in traztuzumab resistance, 533 Fluoropyrimidine, in first-line chemotherapy for metastatic gastric cancer, Fungi, in gastric microbiome, Fusobacterium sp, epidemiologic association with gastric diseases, 399 G Gastric cancers. See also Gastroesophageal cancers. metastatic, management of, first-line chemotherapy, fluoropyrimidines, for HER2-positive disease, platinum compounds, 472 standard regimens, 475 triplet combinations with epirubicin or docetaxel, second-line chemotherapy, special situations, metastatectomy, 479 peritonectomy, 479 synchronous metastases, treatment goals, staging in, cancer of the gastroesophageal junction, CT, endoscopic ultrasound and endoscopic resection, MRI, 435 PET-CT, staging laparoscopy, 436 Gastric microbiome. See Microbiome, gastric. Gastroesophageal cancers. See also Esophageal cancers and Gastric cancers. antiangiogenic therapy in,

6 558 Index Gastroesophageal (continued ) angiogenesis pathway, 500 inhibitors of VEGF axis via monoclonal antibodies, anti-vegf monoclonal antibody, anti-vegfr2 monoclonal antibody, locally advanced disease, 505 ongoing areas of research, combination with anti-her2 therapy, 506 combination with immune checkpoint therapy, predictive biomarkers, tyrosine kinase inhibition of VEGF axis, 504 apatinib in third-line therapy, 504 regorafenib in second/third-line therapy, 504 emerging novel therapeutic agents for gastroesophageal and gastric, cancer stem cells, signal transducers and activators of transcription 3 (STAT3) inhibitors, CLDN18.2 inhibitors, fibroblast growth factor receptor 2 (FGFR2) inhibitors, AZD4547, resistance to, 533 role in trastuzumab resistance, 533 matrix metalloproteinase (MMP) inhibitors, marimastat, 541 specific MMP 9 inhibitors, evolving role of checkpoint inhibitors in, adjuvant studies, efficacy of CTLA-4 inhibitors, 491 ipilumumab or tremelimumab, 491 efficacy of PD-1/PD-L1 inhibitors, avelumab, durvalumab, 491 nivolumab, 490 pembrolizumab, localized, role of radiotherapy in, in esophageal cancer, in gastric cancer, PD-L1 expression in, 488 predictive biomarkers to guide use of, gene signatures, 489 mononuclear inflammatory score, PD-L1/PD-L2 status, 488 rationale for investigating, chronic inflammation, 487 genomic instability, 487 high somatic burden, 487 infection, future directions in improving outcomes, disease prevention, in locally advanced disease, application of novel imaging to identify response, integration of targeted therapies, 549 molecular classification of disease,

7 Index 559 gastroesophageal, targeted therapies for, epidermal growth factor receptor, ERBB2 (HER2), MET, localized, role of radiotherapy in, emerging technologies, image-guided, MRI-guided, proton therapy, in esophageal cancer, definitive chemoradiation, neoadjuvant chemoradiation, in gastric cancer, adjuvant chemoradiation, neoadjuvant chemoradiation, locally advanced, management of, differences in anatomic location and histology, multimodal treatment options, adjuvant chemoradiation, perioperative chemotherapy, preoperative chemoradiation, options to improve current approaches, adaptive therapy based on early response prediction, 446 optimization by targeted therapy, 447 overview, 442 Gastroesophageal junction, staging of cancer of, 428 Gastroesophageal reflux disease (GERD), management of, in Barrett s esophagus, 415 H Helicobacter pylori, disease prevention and improved outcomes with gastroesophageal cancers, epidemiologic association with gastric diseases, evidence for prolonged microbiome shifts associated with prior infection with, mechanisms of tumorigenicity, Histology, of gastroesophageal cancers, impact on management, Human epidermal growth factor 2 (HER2), anti-her2 therapy in combination with antiangiogenic therapy, 506 HER2-positive metastatic gastric cancer, first-line chemotherapy for, Human papillomavirus (HPV), risk factor for Barrett s esophagus and esophageal adenocarcinoma, 410 I Immune checkpoint therapy. See Checkpoint inhibitors. Immunotherapy. See Antiangiogenic therapy. Ipilimumab, efficacy in gastroesophageal cancer management, 491 L Laparoscopy, staging, for esophageal and gastric cancers, 437 Locally advance gastroesophageal cancers antiangiogenic therapy in, 505

8 560 Index Locally (continued) future directions in improving outcomes of, integration of targeted therapies, 549 novel imaging to identify response, management of, differences in anatomic location and histology, multimodal treatment options, adjuvant chemoradiation, perioperative chemotherapy, preoperative chemoradiation, options to improve current approaches, adaptive therapy based on early response prediction, 446 optimization by targeted therapy, 447 overview, 442 M Magnetic resonance imaging (MRI), MRI-guided radiation therapy for esophageal and gastric cancers, for staging esophageal and gastric cancers, 435 Marimastat, for gastroesophageal and gastric adenocarcinomas, 541 Matrix metalloproteinase (MMP) inhibitors, for gastroesophageal and gastric adenocarcinomas, marimastat, 541 specific MMP 9 inhibitors, MET protooncogene, in targeted therapies for gastroesophageal adenocarcinoma, Metastatectomy, in management of metastatic gastric cancer, 479 Metastatic cancer, gastric, management of, first-line chemotherapy, fluoropyrimidines, for HER2-positive disease, platinum compounds, 472 standard regimens, triple combinations with epirubicin or docetaxel, second-line chemotherapy, special situations, metastatectomy, 479 peritonectomy, 479 synchronous metastases, treatment goals, Microbiome, gastric, influence on gastric carcinogenesis, community dynamics and pathobionts, diversity of along the GI tract, archaea, 393 esophageal bacteria, fungi, gastric bacteria, viruses, epidemiologic associations with diseases, Epstein-Barr virus, 396

9 Index 561 Helicobacter pylori, other, 396 evidence for microbiome shifts with prior Helicobacter pylori infection, Epstein-Barr virus, 398 Fusobacterium sp, 399 other species, 399 identification methodologies from clinical samples, computational identification, experimental approaches, 394 molecular associations and mechanisms of carcinogenesis, Helicobacter pylori tumorigenicity, Molecular profiling, in improving outcomes with gastroesophageal cancers, MRI-guided radiation therapy, for localized esophageal and gastric cancers, Multimodal therapy, of locally advanced gastroesophageal cancers, N Napabucasin (BBI-608), novel therapy for gastroesophageal and gastric adenocarcinomas, with weekly paclitaxel, Neoadjuvant therapy, chemoradiation for localized esophageal cancer, chemoradiation for localized gastric cancer, chemoradiation for locally advanced gastroesophageal cancers, Nivolumab, efficacy in gastroesophageal cancer management, 490 Nonsteroidal antiinflammatory drugs (NSAIDs), for Barrett s esophagus, 416 O Outcomes, with gastroesophageal cancer, future directions in improving, disease prevention, in locally advanced disease, application of novel imaging to identify response, integration of targeted therapies, 549 molecular classification of disease, P Paclitaxel, weekly, with napabucasin (BBI-608) for gastroesophageal and gastric adenocarcinomas, Pembrolizumab, efficacy in gastroesophageal cancer management, Peritonectomy, in management of metastatic gastric cancer, 479 Platinum compounds, in first-line chemotherapy for metastatic gastric cancer, 472 Positron emission tomography (PET), with CT for staging esophageal and gastric cancers, Prevention, in improving outcomes with gastroesophageal cancers, Programmed death ligand 1 (PD-L1), efficacy of PD-1/PD-L1 inhibitors in gastroesophageal cancer, avelumab, durvalumab, 491 nivolumab, 490 pembrolizumab, expression in gastroesophageal cancer, 488

10 562 Index Programmed (continued) PD-L1/PD-L2 status as predictive biomarker in gastroesophageal cancer, 488 Proton pump inhibitors, for Barrett s esophagus, Proton therapy, for localized esophageal and gastric cancers, R Radiotherapy, role in localized esophageal and gastric cancer, emerging technologies, image-guided, MRI-guided, proton therapy, in esophageal cancer, definitive chemoradiation, neoadjuvant chemoradiation, in gastric cancer, adjuvant chemoradiation, neoadjuvant chemoradiation, Regorafenib, for gastroesophageal cancer therapy, 504 Resection, endoscopic, for staging esophageal and gastric cancers, S Signal transducers and activators of transcription 3 (STAT3) inhibitors, in novel therapies for gastroesophageal and gastric adenocarcinomas, combination of BBI-608 and weekly paclitaxel, napabucasin (BBI-608), 538 OPB-31121, 538 OPB-51602, 538 Staging, in esophageal and gastric cancers, cancer of the gastroesophageal junction, CT, endoscopic ultrasound and endoscopic resection, MRI, 435 PET-CT, staging laparoscopy, 436 Stem cells, cancer, in novel therapies for gastroesophageal and gastric adenocarcinomas, Surveillance, endoscopic, of Barrett s esophagus, 414 Synchronous metastases, of gastric cancer, management of, T Targeted therapies, for gastroesophageal adenocarcinoma, epidermal growth factor receptor, ERBB2 (HER2), MET, for locally advanced gastroesophageal cancers, 447 role in improving outcomes for gastroesophageal cancer, Trastuzumab, in targeted therapy of gastroesophageal adenocarcinoma, role of FGFR in resistance to, 533

11 Index 563 Tremelimumab, efficacy in gastroesophageal cancer management, 491 Triplet combinations, in first-line chemotherapy for metastatic gastric cancer, Tyrosine kinase inhibition, of VEGF axis, 504 apatinib in third-line therapy, 504 regorafenib in second/third-line therapy, 504 U Ultrasound, endoscopic, for staging esophageal and gastric cancers, Upper gastrointestinal malignancies, antiangiogenic therapy in, Barrett esophagus and intramucosal esophageal adenocarcinoma, checkpoint inhibitors role in, emerging novel therapeutic agents, future directions in improving outcomes of, gastric microbiome and gastric carcinogenesis, locally advanced gastroesophageal cancer, metastatic gastric cancer, radiotherapy for localized esophageal and gastric cancer, staging in esophageal and gastric cancers, targeted therapies for adenocarcinoma, V Vascular endothelial growth factor (VEGF) axis, inhibition of via monoclonal antibodies, anti-vegf monoclonal antibody, anti-vegfr2 monoclonal antibody, Viruses, in gastric microbiome,